FBXO17

Summary

FBXO17 (F-box protein 17, HGNC:18754) is a protein-coding gene on chromosome 19q13.2, encoding F-box only protein 17 (Q96EF6). Substrate-recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex.

This gene encodes a member of the F-box protein family which is characterized by the F-box motif. The F-box proteins constitute one of the four subunits of the ubiquitin protein ligase complex called SCFs (SKP1-cullin-F-box), which function in phosphorylation-dependent ubiquitination. The F-box proteins are divided into 3 classes: Fbws containing WD-40 domains, Fbls containing leucine-rich repeats, and Fbxs containing either different protein-protein interaction modules or no recognizable motifs. The protein encoded by this gene belongs to the Fbxs class and it contains an F-box domain. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 115290 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 67 total
• MANE Select transcript: NM_024907

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18754
Approved symbol	FBXO17
Name	F-box protein 17
Location	19q13.2
Locus type	gene with protein product
Status	Approved
Aliases	FBG4, FLJ25205, MGC9379, FLJ11798, Fbx17
Ensembl gene	ENSG00000269190
Ensembl biotype	protein_coding
OMIM	609094
Entrez	115290

Gene structure

Transcript identifiers

Ensembl transcripts: 25 — 21 protein_coding, 2 nonsense_mediated_decay, 2 retained_intron

ENST00000292852, ENST00000595329, ENST00000596025, ENST00000597696, ENST00000599418, ENST00000599598, ENST00000601394, ENST00000856598, ENST00000856599, ENST00000856600, ENST00000856601, ENST00000856602, ENST00000856603, ENST00000856604, ENST00000856605, ENST00000856606, ENST00000856607, ENST00000856608, ENST00000939439, ENST00000939440, ENST00000939441, ENST00000939442, ENST00000944470, ENST00000944471, ENST00000944472

RefSeq mRNA: 2 — MANE Select: NM_024907 NM_024907, NM_148169

CCDS: CCDS12526

Canonical transcript exons

ENST00000292852 — 6 exons

Exon	Start	End
ENSE00001199310	38941401	38942751
ENSE00002493229	38949971	38950336
ENSE00003127372	38975586	38975742
ENSE00003458936	38948567	38948678
ENSE00003481172	38946472	38946567
ENSE00003642065	38944969	38945104

Expression profiles

Bgee: expression breadth ubiquitous, 135 present calls, max score 95.42.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 7.0830 / max 57.8243, expressed in 1379 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
180834	6.3800	1370
180835	0.7030	475

Top tissues by expression

139 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	95.42	gold quality
metanephros cortex	UBERON:0010533	94.00	gold quality
adult mammalian kidney	UBERON:0000082	93.06	gold quality
right ovary	UBERON:0002118	93.05	gold quality
cortex of kidney	UBERON:0001225	93.01	gold quality
left ovary	UBERON:0002119	92.72	gold quality
mucosa of stomach	UBERON:0001199	92.58	gold quality
ovary	UBERON:0000992	92.42	gold quality
liver	UBERON:0002107	92.41	gold quality
kidney	UBERON:0002113	92.14	gold quality
body of uterus	UBERON:0009853	91.99	gold quality
endocervix	UBERON:0000458	91.88	gold quality
myometrium	UBERON:0001296	90.94	gold quality
tibial artery	UBERON:0007610	90.79	gold quality
popliteal artery	UBERON:0002250	90.78	gold quality
subcutaneous adipose tissue	UBERON:0002190	90.75	gold quality
right hemisphere of cerebellum	UBERON:0014890	90.48	gold quality
cerebellar hemisphere	UBERON:0002245	90.42	gold quality
cerebellar cortex	UBERON:0002129	90.36	gold quality
cerebellum	UBERON:0002037	90.32	gold quality
left uterine tube	UBERON:0001303	90.22	gold quality
adipose tissue	UBERON:0001013	89.79	gold quality
tibial nerve	UBERON:0001323	89.59	gold quality
right coronary artery	UBERON:0001625	89.48	gold quality
ascending aorta	UBERON:0001496	89.44	gold quality
thoracic aorta	UBERON:0001515	89.39	gold quality
ectocervix	UBERON:0012249	89.30	gold quality
descending thoracic aorta	UBERON:0002345	89.24	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	88.92	gold quality
left coronary artery	UBERON:0001626	88.81	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.11
E-MTAB-6386	no	3.23

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

50 targeting FBXO17, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-12122	99.56	69.33	1672
HSA-MIR-6165	99.44	67.12	1389
HSA-MIR-3064-5P	99.26	66.13	1497
HSA-MIR-3085-3P	99.26	66.16	1490
HSA-MIR-6504-5P	99.26	65.95	1487
HSA-MIR-149-5P	99.25	67.16	1315
HSA-MIR-7160-5P	99.11	67.17	2207
HSA-MIR-4434	99.10	67.01	1984
HSA-MIR-5703	99.10	67.09	2053
HSA-MIR-328-5P	99.08	64.65	1000
HSA-MIR-10B-3P	99.04	66.98	988
HSA-MIR-4742-5P	98.89	68.41	1542
HSA-MIR-6829-5P	98.86	65.12	1480
HSA-MIR-6846-5P	98.81	65.86	1121
HSA-MIR-6848-5P	98.81	65.49	1126
HSA-MIR-4656	98.79	66.22	1306
HSA-MIR-6885-5P	98.71	64.33	902
HSA-MIR-1227-5P	98.65	65.32	1549
HSA-MIR-4722-5P	98.46	66.34	1611

Literature-anchored findings (GeneRIF, showing 10)

• the apparent occurrence of an unusual TG 3’ splice site in intron 3 is discussed (PMID:17672918)
• our studies identify a previously unreported role of FBXO17 in regulating IFN-I signaling (PMID:27956528)
• identified FBXO17 as an F-box protein subunit that recognizes and mediates GSK3beta polyubiquitination. (PMID:28298444)
• Studied expression levels of F-box protein 17 (FBX017) in high grade gliomas; found patients with higher FBXO17 expression had a shorter overall survival. (PMID:30064493)
• These data support a role for FBXO17 overexpression in regulating cell proliferation and survival through modulation of Akt and ERK kinase activation and a potential role for the F-box subunit in modulating tumorigenesis in lung cancers. (PMID:30359271)
• FBXO17 promotes malignant progression of hepatocellular carcinoma by activating wnt/beta-catenin pathway. (PMID:31646557)
• Identification and validation of an immune-associated RNA-binding proteins signature to predict clinical outcomes and therapeutic responses in colon cancer patients. (PMID:34702278)
• F-box protein 17 promotes glioma progression by regulating glycolysis pathway. (PMID:35044455)
• Circ_0008717 promotes renal cell carcinoma progression by upregulating FBXO17 via targeting miR-217. (PMID:35357059)
• FBXO17 Inhibits the Wnt/beta-Catenin Pathway and Proliferation of Ishikawa Cells. (PMID:36035375)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Fbxo17	ENSMUSG00000030598
rattus_norvegicus	Fbxo17	ENSRNOG00000019942

Paralogs (5): FBXO2 (ENSG00000116661), FBXO6 (ENSG00000116663), FBXO44 (ENSG00000132879), FBXO27 (ENSG00000161243), NCCRP1 (ENSG00000188505)

Protein

Protein identifiers

F-box only protein 17 — Q96EF6 (reviewed: Q96EF6)

Alternative names: F-box only protein 26

All UniProt accessions (4): Q96EF6, M0QYI3, M0QYV7, M0QZ95

UniProt curated annotations — full annotation on UniProt →

Function. Substrate-recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex. Able to recognize and bind denatured glycoproteins, which are modified with complex-type oligosaccharides. Also recognizes sulfated glycans. Does not bind high-mannose glycoproteins.

Subunit / interactions. Part of a SCF (SKP1-cullin-F-box) protein ligase complex. Interacts with SKP1 and CUL1.

Tissue specificity. Expressed in heart, skeletal muscle, liver and kidney. Expressed at lower levels in spleen and brain.

RefSeq proteins (2): NP_079183, NP_680474 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001810	F-box_dom	Domain
IPR007397	F-box-assoc_dom	Domain
IPR008979	Galactose-bd-like_sf	Homologous_superfamily
IPR036047	F-box-like_dom_sf	Homologous_superfamily
IPR039752	F-box_only	Family

Pfam: PF04300, PF12937

UniProt features (4 total): domain 2, chain 1, mutagenesis site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96EF6-F1	90.35	0.78

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (1):

Position	Phenotype
257–258	reduces interaction with glycosylated concanavalin-a in vitro.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-8951664	Neddylation
R-HSA-983168	Antigen processing: Ubiquitination & Proteasome degradation

MSigDB gene sets: 118 (showing top): GOBP_RESPONSE_TO_NITROGEN_COMPOUND, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION, GOBP_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_CATABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_SCF_DEPENDENT_PROTEASOMAL_UBIQUITIN_DEPENDENT_PROTEIN_CATABOLIC_PROCESS, GOBP_PROTEASOMAL_PROTEIN_CATABOLIC_PROCESS, GOBP_ERAD_PATHWAY, GOBP_PROTEIN_CATABOLIC_PROCESS, GOBP_GLYCOPROTEIN_METABOLIC_PROCESS, GOCC_SCF_UBIQUITIN_LIGASE_COMPLEX, GOCC_TRANSFERASE_COMPLEX

GO Biological Process (3): glycoprotein catabolic process (GO:0006516), SCF-dependent proteasomal ubiquitin-dependent protein catabolic process (GO:0031146), ERAD pathway (GO:0036503)

GO Molecular Function (2): protein binding (GO:0005515), ubiquitin protein ligase activity (GO:0061630)

GO Cellular Component (3): cytoplasm (GO:0005737), cytosol (GO:0005829), SCF ubiquitin ligase complex (GO:0019005)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Post-translational protein modification	1
Class I MHC mediated antigen processing & presentation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
glycoprotein metabolic process	1
protein catabolic process	1
carbohydrate derivative catabolic process	1
proteasome-mediated ubiquitin-dependent protein catabolic process	1
proteasomal protein catabolic process	1
response to endoplasmic reticulum stress	1
response to chemical	1
binding	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
intracellular anatomical structure	1
cytoplasm	1
cullin-RING ubiquitin ligase complex	1

Protein interactions and networks

STRING

456 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FBXO17	SKP1	P34991	708
FBXO17	CUL1	Q13616	686
FBXO17	B7Z1P2	B7Z1P2	593
FBXO17	FBXL3	Q9UKT7	537
FBXO17	FBXO2	Q9UK22	480
FBXO17	ELOVL2	Q9NXB9	438
FBXO17	FBXO42	Q6P3S6	435
FBXO17	FBXO27	Q8NI29	402
FBXO17	FBXW12	Q6X9E4	393
FBXO17	FBXO16	Q8IX29	376
FBXO17	GOLGA6L9	A6NEM1	370
FBXO17	FBXO9	Q9UK97	350
FBXO17	FBXL19	Q6PCT2	348
FBXO17	SH3RF1	Q7Z6J0	341
FBXO17	FBXL22	Q6P050	341

IntAct

113 interactions, top by confidence:

A	B	Type	Score
SKP1	FBXO17	psi-mi:“MI:0915”(physical association)	0.920
FBXO17	SKP1	psi-mi:“MI:0915”(physical association)	0.920
KLHL12	CUL3	psi-mi:“MI:0914”(association)	0.920
FBXO17	CUL1	psi-mi:“MI:0915”(physical association)	0.790
COPS6	RHOBTB1	psi-mi:“MI:0914”(association)	0.730
SKP1	MYCBP2	psi-mi:“MI:0914”(association)	0.640
CUL1	FBXO21	psi-mi:“MI:0914”(association)	0.600
FBXO17	CDCA8	psi-mi:“MI:0915”(physical association)	0.560
KPRP	FBXO17	psi-mi:“MI:0915”(physical association)	0.560
RUNX1	FBXO17	psi-mi:“MI:0915”(physical association)	0.560
DZIP3	FBXO17	psi-mi:“MI:0915”(physical association)	0.560
ADAMTSL4	FBXO17	psi-mi:“MI:0915”(physical association)	0.560
KRT75	FBXO17	psi-mi:“MI:0915”(physical association)	0.560
USP54	FBXO17	psi-mi:“MI:0915”(physical association)	0.560
SAXO1	FBXO17	psi-mi:“MI:0915”(physical association)	0.560
CBY2	FBXO17	psi-mi:“MI:0915”(physical association)	0.560
PTPN21	FBXO17	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (107): FBXO17 (Two-hybrid), HSPD1 (Affinity Capture-MS), NMT1 (Affinity Capture-MS), NMT2 (Affinity Capture-MS), COPS2 (Affinity Capture-MS), NDUFA2 (Affinity Capture-MS), COPS7B (Affinity Capture-MS), COPS4 (Affinity Capture-MS), SKP1 (Affinity Capture-MS), CUL1 (Affinity Capture-MS), COPS6 (Affinity Capture-MS), CLPP (Affinity Capture-MS), SARS2 (Affinity Capture-MS), COPS5 (Affinity Capture-MS), FBXW2 (Affinity Capture-MS)

ESM2 similar proteins: A5PJU7, A8MQ27, F1MLB4, F1MX48, F1SAM7, I3L5V6, O75425, O95382, P36916, Q08DG4, Q0MW30, Q14451, Q2YD98, Q32P44, Q3MIP1, Q3T033, Q3UPE3, Q3UV16, Q505F5, Q5EBM0, Q5U651, Q5ZM20, Q641Q3, Q6MG06, Q6SZW1, Q6ZTW0, Q7T0L4, Q8BGG6, Q8BH83, Q8C0R7, Q8K0Y7, Q8N9W5, Q8R2K4, Q8TE68, Q8VC03, Q96BM1, Q96E14, Q96EF6, Q96EY9, Q99JB7

Diamond homologs: G3X9C2, Q17QK6, Q3SX24, Q568V3, Q6AY27, Q6DIA9, Q6ZVX7, Q80UW2, Q8NI29, Q923V4, Q96EF6, Q9H4M3, Q9N0C8, Q9NRD1, Q9QZM8, Q9UK22, Q8BK26, Q9QZN4

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 54 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
DNA Damage Recognition in GG-NER	7	52.6×	8e-09
Formation of TC-NER Pre-Incision Complex	7	39.0×	5e-08
GSK3B-mediated proteasomal degradation of PD-L1(CD274)	5	31.3×	3e-05
Cargo recognition for clathrin-mediated endocytosis	7	19.3×	5e-06
Neddylation	13	16.2×	2e-10
Antigen processing: Ubiquitination & Proteasome degradation	9	8.8×	3e-05

GO biological processes:

GO term	Partners	Fold	FDR
regulation of protein neddylation	5	93.6×	2e-07
protein neddylation	6	84.3×	2e-08
protein monoubiquitination	5	34.4×	3e-05
protein K48-linked ubiquitination	5	16.9×	5e-04
protein ubiquitination	9	7.5×	2e-04
proteasome-mediated ubiquitin-dependent protein catabolic process	7	7.3×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

67 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	55
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1844 predictions. Top by Δscore:

Variant	Effect	Δscore
19:38942748:AGACC:A	acceptor_loss	1.0000
19:38942749:GACCT:G	acceptor_loss	1.0000
19:38942752:C:CG	acceptor_loss	1.0000
19:38942753:T:C	acceptor_loss	1.0000
19:38948565:A:AC	donor_gain	1.0000
19:38948566:C:CC	donor_gain	1.0000
19:38948566:CT:C	donor_gain	1.0000
19:38948675:CCCT:C	acceptor_gain	1.0000
19:38948676:CCTC:C	acceptor_gain	1.0000
19:38948679:C:CC	acceptor_gain	1.0000
19:38949970:CG:C	donor_gain	1.0000
19:38949970:CGCT:C	donor_gain	1.0000
19:38949975:T:A	donor_gain	1.0000
19:38950054:T:TA	donor_gain	1.0000
19:38942681:A:AC	donor_gain	0.9900
19:38942682:C:CC	donor_gain	0.9900
19:38942682:CGT:C	donor_gain	0.9900
19:38942694:A:AC	donor_gain	0.9900
19:38942695:C:CC	donor_gain	0.9900
19:38942695:CTG:C	donor_gain	0.9900
19:38946564:CCAT:C	acceptor_gain	0.9900
19:38946565:CATC:C	acceptor_gain	0.9900
19:38948552:A:AC	donor_gain	0.9900
19:38948553:C:CC	donor_gain	0.9900
19:38948559:CCACT:C	donor_loss	0.9900
19:38948561:ACTCA:A	donor_loss	0.9900
19:38948562:CT:C	donor_loss	0.9900
19:38948562:CTCAC:C	donor_loss	0.9900
19:38948563:T:TA	donor_loss	0.9900
19:38948563:T:TG	donor_loss	0.9900

AlphaMissense

1774 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:38948581:G:C	F149L	0.995
19:38948581:G:T	F149L	0.995
19:38948583:A:G	F149L	0.995
19:38946555:C:A	K158N	0.994
19:38946555:C:G	K158N	0.994
19:38945020:G:C	F214L	0.993
19:38945020:G:T	F214L	0.993
19:38945022:A:G	F214L	0.993
19:38948664:A:G	W122R	0.992
19:38948664:A:T	W122R	0.992
19:38942737:G:C	F236L	0.991
19:38942737:G:T	F236L	0.991
19:38942739:A:G	F236L	0.991
19:38948637:A:G	W131R	0.991
19:38948637:A:T	W131R	0.991
19:38942738:A:G	F236S	0.990
19:38948662:C:A	W122C	0.990
19:38948662:C:G	W122C	0.990
19:38946487:A:G	I181T	0.987
19:38948569:G:C	F153L	0.987
19:38948569:G:T	F153L	0.987
19:38948571:A:G	F153L	0.987
19:38946527:C:A	G168W	0.986
19:38948576:G:A	T151I	0.986
19:38948582:A:C	F149C	0.985
19:38948582:A:G	F149S	0.985
19:38948635:C:A	W131C	0.984
19:38948635:C:G	W131C	0.984
19:38942701:A:C	F248L	0.983
19:38942701:A:T	F248L	0.983

dbSNP variants (sampled 300 via entrez): RS1000059468 (19:38944728 G>T), RS1000092632 (19:38976627 C>T), RS1000190912 (19:38962540 C>T), RS1000288286 (19:38969198 C>T), RS1000439472 (19:38976694 A>G,T), RS1000445260 (19:38968960 G>T), RS1000640327 (19:38963714 A>C,T), RS1000671040 (19:38971106 A>C), RS1000816801 (19:38944524 A>G), RS1000894652 (19:38944289 T>C), RS1000932020 (19:38963879 G>A), RS1001097162 (19:38956851 C>A,T), RS1001127223 (19:38951029 A>G), RS1001145599 (19:38945156 G>A), RS1001229396 (19:38952136 TG>T)

Disease associations

OMIM: gene MIM:609094 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST012256_17	SAPHO syndrome	2.000000e-07

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression, decreases methylation, increases methylation	3
Valproic Acid	affects expression, decreases expression	3
sodium arsenite	affects methylation, decreases expression	2
bisphenol A	increases expression	1
beta-lapachone	decreases expression	1
methylparaben	increases expression	1
benzo(e)pyrene	decreases methylation	1
aflatoxin B2	decreases methylation	1
CGP 52608	affects binding, increases reaction	1
ICG 001	increases expression	1
jinfukang	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Carbamazepine	affects expression	1
Doxorubicin	increases expression	1
Methapyrilene	decreases methylation	1
Phenylmercuric Acetate	decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Quercetin	increases expression	1
Selenium	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tunicamycin	increases expression	1
Urethane	decreases expression	1
Vitamin E	increases expression	1
Aflatoxin B1	decreases methylation	1
Antirheumatic Agents	increases expression	1
Okadaic Acid	decreases expression	1
Acrylamide	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.